MA 07.13 NGS Sequencing Based Liquid / Tissue Biopsy Identified Coexistence of HER2 Amplification and Mutation in Advanced NSCLC Patients

Chen, R.; Zhao, Jun; Lin, Gen; Liu, Ling; Chen, L.; Hu, Xiaoyi; Ai, X.; Zhang, Fan; Xu, Chunfang; Wang, W.; Zhuang, Wenxin; Fang, Min; Zhu, Y.; Chen, G.; Guan, Y.; Yang, L.; Xia, X.; Yi, X.

doi:10.1016/j.jtho.2017.09.513

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, the NGS method has been commonly used for HER2 amplification detection (30). A previous study indicated that NGS can identify the coexistence of HER2 amplification and mutation in NSCLC (31). However, NGS also has disadvantages; its application is limited by the reading length of 200-500 bp segments (32).…”

Section: Discussionmentioning

confidence: 99%

Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer

Qi¹,

Xiong²,

Jiang³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer

Qi¹,

Xiong²,

Jiang³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

“…Studies have shown that HER2 amplification and HER2 mutations were distinct molecular targets that may have different therapeutic and prognostic values. But they could co-exist in very few cases ( 9 , 19 ). Though an official consensus is not available, generally HER2 amplification is defined as HER2/CEP17 ≥ 2.0 by fluorescent in situ hybridization (FISH) testing.…”

Section: The Biology Of Her2 and Its Dysregulation In Nsclcmentioning

confidence: 99%

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies

2022

Front. Oncol.

View full text Add to dashboard Cite

Multiple oncogenic molecular alterations have been discovered that serve as potential drug targets in non-small cell lung cancer (NSCLC). While the pathogenic and pharmacological features of common targets in NSCLC have been widely investigated, those of uncommon targets are still needed to be clarified. Human epidermal growth factor receptor 2 (HER2, ERBB2)-altered tumors represent a highly heterogeneous group of diseases, which consists of three distinct situations including mutation, amplification and overexpression. Compared with breast and gastric cancer, previous studies have shown modest and variable results of anti-HER2 treatments in lung cancers with HER2 aberrations, thus effective therapies in these patients represent an unmet medical need. By far, encouraging efforts towards novel treatment strategies have been made to improve the clinical outcomes of these patients. In this review, we describe the biological and clinicopathological characteristics of HER2 alterations and systematically sum up recent studies on emerging therapies for this subset of patients.

show abstract

“…In addition, several retrospective studies have shown that the most common type of HER2 mutation was inframe insertions in exon 20. 15,16,18,20 Chen et al 21 analyzed 54 tissue and blood samples of 48 patients with HER2 gene mutation or amplification and found that 36 samples harbored HER2 gene mutation and 23 samples showed HER2 gene amplification. Li et al 22 identified four cases of HER2 gene mutation without gene amplification and overexpression by FISH and IHC, respectively.…”

Section: Her2 Mutation In Nsclcmentioning

confidence: 99%

Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations

Ni¹,

Zhang²

2021

OTT

View full text Add to dashboard Cite

Epidermal growth factor receptor 2 (HER2/ErbB2/neu), a member of ErbB receptor tyrosine kinase family, forms homo-or heterodimers with ErbB1 (HER1/EGFR), ErbB3 (HER3), or ErbB4 (HER4), to activate signal transduction pathways and promote proliferation, differentiation and tumorigenesis. Preliminary clinical trials of monoclonal antibodies, antibody conjugates and small-molecule tyrosine kinase inhibitors targeting HER2 have indicated that HER2 is a potential therapeutic target in non-small cell lung cancer (NSCLC). HER2 aberrations in NSCLC patients mainly include mutation, amplification, and overexpression. While there are significant differences in the outcome of NSCLC with these HER2 changes, no consensus has been reached for the incidence, detection method and targeted treatments for the three types of HER2 aberration. HER2 mutation is generally considered to have more clinical relevance and response to HER2-targeted therapies. In this review, we discuss HER2 alterations in NSCLC, including diagnostic challenges and treatment strategies particular to the HER2 mutation.

show abstract

MA 07.13 NGS Sequencing Based Liquid / Tissue Biopsy Identified Coexistence of HER2 Amplification and Mutation in Advanced NSCLC Patients

Cited by 6 publications

References 0 publications

Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer

Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies

Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations

Contact Info

Product

Resources

About